Search

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

Blood Disorders: European Hematologists gather in Stockholm, June 13-16, 2013

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more

Professor Degos awarded at the 17th Congress of EHA in Amsterdam

Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.

Read more

Secondary leukemogenesis in the context of T-cell based immunotherapies project

An SWG Grant-supported project initiated by the EHA SWG on Immune Therapies for Hematologic Disorders.

Read more

Epidemiology of infection in AML: A European Hematology Association survey (EPIAMLINF)

Project team

Jon Salmanton-García
Institution: University of Cologne, Germany

Biography: My research focuses on infectious diseases in hematology, particularly fungal infections and viral complications in immunocompromised patients.

Read more

EHA Mentorship Program eligibility

Before applying for the EHA Mentorship Program, please consider the eligibility criteria on this page. You should also read our policy on life events.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more